Kwangdong Pharmaceutical (CEO Choi Seong-won) announced on the 13th that it will begin full-scale activities to provide medical information to medical staff about Moderna's newly updated COVID-19 vaccine 'Spikevax X', which was recently approved by the Ministry of Food and Drug Safety.

Moderna's monovalent vaccine against the XBB.1.5 mutation contains neutralizing antibodies against prevalent mutations such as BA.2.86, EG.5, and FL.1.5.1, as well as the Clinical data confirming the response has been published. The vaccine approved this time is for those 12 years of age or older, and is strongly recommended for the elderly, those with weakened immune systems, and members of facilities vulnerable to infec